cisapride has been researched along with Cancer of Lung in 1 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Incorporation of these olefins into the quinazoline templates produced potent EGFR inhibitors with improved safety and pharmacokinetic properties." | 1.40 | A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. ( Chen, W; Deng, H; Han, J; Huang, W; Li, B; Li, P; Li, Y; Liu, Y; Ma, C; Miao, H; Qi, W; Shao, J; Shen, J; Sun, X; Xia, G; Xiang, Z; Xu, J; Yu, Y; Zhang, J; Zhang, L; Zhang, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, G | 1 |
| Chen, W | 1 |
| Zhang, J | 1 |
| Shao, J | 1 |
| Zhang, Y | 1 |
| Huang, W | 1 |
| Zhang, L | 1 |
| Qi, W | 1 |
| Sun, X | 1 |
| Li, B | 1 |
| Xiang, Z | 1 |
| Ma, C | 1 |
| Xu, J | 1 |
| Deng, H | 1 |
| Li, Y | 1 |
| Li, P | 1 |
| Miao, H | 1 |
| Han, J | 1 |
| Liu, Y | 1 |
| Shen, J | 1 |
| Yu, Y | 1 |
1 other study available for cisapride and Cancer of Lung
| Article | Year |
|---|---|
A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Ether-A | 2014 |